Vendor Intelligence Report: SRY Labs

Published 12 Jun 2026. 28-page investigative report on who is behind SRY Labs: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

SRY Labs is not a simple quality story. Across 120 Finnrick lab tests, the vendor records 77 pass / 43 fail — an overall pass rate of 64%. The customer-provided sample record is sharply split: tirzepatide and retatrutide both test above 90%, while tesamorelin and CJC-1295 are among the weakest signals. Under stricter grading, the acceptable universe narrows further, so SRY is a product-specific decision rather than a vendor-wide trust decision.

The counterparty file is heavier than the lab headline. The report traces a short 2023 domain/entity history, Shanghai branding, a Guangdong operational trail, and contact infrastructure shared with a Dongguan houseware business. Separately, charging papers and federal docket records show Shanghai Senria under a pending U.S. indictment alleging protonitazene importation and international money laundering; the absence of a sanctions listing does not remove that exposure.

SRY's buyer-facing footprint also runs through forums and direct reps, not a clean verifiable storefront. The forum record is treated with caveats, but the pattern is specific: alleged withheld failed tests, water/oil formulation mislabeling, double-order payment demands, ghosting after disputes, and a later restart through newer channels. For a buyer already set on SRY, the full report separates the relatively defensible GLP-1 choices from the legacy-peptide orders where the independent record points elsewhere.

Inside the full report:

  • Appendix A Finnrick laboratory data, per-product pass/fail rates and methodology-divergence charts for all 11 products
  • WHOIS, Wayback, ICP and Chinese registry exhibits mapping the domain and Shanghai/Guangdong address trail
  • U-Hanger contact-infrastructure comparison using SRY's archived About page and Universal Houseware records
  • U.S. indictment, DOJ/DEA releases and CourtListener docket analysis for the Senria/Zhenbo Han case
  • Forum incident chronology covering concealed-test allegations, formulation mislabeling, payment demands and 2025-26 channel changes
  • Risk matrix and product-specific buyer guidance for GLP-1 versus legacy peptide orders

Risk assessment

  • Controlled-substance prosecution risk — high: Shanghai Senria and Zhenbo Han are under a pending U.S. indictment alleging attempted protonitazene importation, customs-evasion tactics and money laundering.
  • Product-specific quality risk — high: Finnrick testing is strong for tirzepatide (92.15%) and retatrutide (90.65%) but fail-heavy for tesamorelin (31.22%), CJC-1295 (25.54%), TB-500 (34.8%), BPC-157 (41.4%), Sermorelin (37.37%) and PT-141 (47.49%).
  • Forum-reported transaction and mislabeling risk — high: Forum records report concealed failed tests, water/oil formulation mislabeling, 'double-order' payment demands, ghosting and bank-wire fraud flags.
  • Corporate identity and channel-transparency risk — high: Records conflict across Shanghai Senria Biotechnology/New Materials, Shanghai/Fengxian/Lingang/Dongguan addresses, and SRY used contact infrastructure shared with u-hanger.com while its site was unreachable.
  • Operational continuity risk — medium: Forum records describe a September 2025 disruption with unfilled orders followed by March 2026 activity through new representatives, Telegram and the Root app.